News & Press Releases
Filter by:
Inside the Strategy 2 Mintz Attorneys Used to Strike a Mass. Rent Control Initiative From the November Ballot
August 6, 2026
Elissa Flynn-Poppey and Edmund Daley discussed with Law.com the legal strategy behind their successful challenge to a proposed Massachusetts rent control ballot initiative. Their argument that the measure's religious exemption violated Article 48 of the Massachusetts Constitution ultimately led to the initiative's removal from the November 2026 ballot.
Mintz Advises on $200 Million Private Placement Concurrent with Vidya Therapeutics’ and Processa Pharmaceuticals’ Merger Transaction
August 04, 2026
Mintz advised the placement agents on the $200 Million private placement in connection with Processa Pharmaceuticals, Inc.’s acquisition of Vidya Therapeutics, Inc.
Mintz Adds Former ITC Senior Attorney-Advisor to IP Practice, Further Strengthening Life Sciences and Innovation Capabilities
August 04, 2026
WASHINGTON, DC – Mintz is pleased to welcome Michael Leib, former senior attorney-advisor to multiple commissioners at the US International Trade Commission (ITC), to the firm's Intellectual Property Practice as a Member in its Washington, DC, office.
Mintz Earns Firm and Individual Recognition in 2026 IP Stars and Top Women in IP Rankings
August 03, 2026
Several attorneys in Mintz’s Intellectual Property Practice have been recognized in the 2026 edition of IP Stars, published by Managing IP. In addition to individual attorney recognitions, Mintz was recognized in the United States rankings for ITC Litigation, Life Sciences IP, Patent Disputes, PTAB Litigation, and Patent Prosecution.
Mintz advised the placement agents in connection with LB Pharmaceuticals’ $150 Million private placement of common stock and pre-funded warrants.
Mintz Advises Synlogic on Merger with Caldera Therapeutics and $278 Million Private Placement Financing
July 30, 2026
Mintz advised Synlogic, Inc. in its definitive merger agreement with Caldera Therapeutics, Inc. in an all-stock transaction pursuant to which both companies will become wholly owned subsidiaries of a newly formed company that will operate as Caldera Therapeutics, Inc. The transaction is supported by an upsized $278 million concurrent private placement financing from a syndicate of new and existing investors and is expected to close concurrently with the completion of the merger.
